Figure 3
MSP analysis showing EBF3 promoter hypermethylation in AML samples. (A) Western blot analysis depicting the expression of EBF3 in eight NBM samples and nine leukemia cells. (B) MSP analysis the promoter methylation of EBF3 and aberrant EBF3 methylation was observed in 42.9% (45/105) of the pediatric AML samples compared with 13.3% (4/30) of the NBM control samples. M and U represent MSP results using primer sets for methylated and unmethylated EBF3 genes, respectively.